Literature DB >> 11751788

Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock.

Andrea Giacometti1, Oscar Cirioni, Roberto Ghiselli, Federico Mocchegiani, Alessandra Mataloni Paggi, Fiorenza Orlando, Wojciech Kamysz, Franciszek Kasprzykowski, Zbigniew Mackiewicz, Giorgio Scalise, Vittorio Saba.   

Abstract

The efficacy of two polymyxin-like peptides, KFFKFFKFF and IKFLKFLKFL, alone and combined with levofloxacin, was investigated in a rat model of septic shock. Rats were given an ip injection of 2 x 10(10) cfu of Escherichia coli and randomized to receive ip isotonic sodium chloride solution, 7 mg/kg levofloxacin, 1 mg/kg polymyxin B and 1 mg/kg of each polymyxin-like peptides alone or combined with 7 mg/kg levofloxacin. Polymyxins achieved a significant reduction in plasma endotoxin and tumour necrosis factor alpha (TNF-alpha) concentration. Levofloxacin significantly reduced the bacterial growth and TNF-alpha concentration. The combinations of polymyxin-like peptides and levofloxacin demonstrated the highest efficacy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751788     DOI: 10.1093/jac/49.1.193

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  Experimental model for treatment of extended spectrum betalactamase producing-Klebsiella pneumoniae.

Authors:  Paula Virginia Michelon Toledo; Felipe Francisco Tuon; Larissa Bail; Francine Manente; Polliane Arruda; Ayrton Alves Aranha-Junior
Journal:  Arq Bras Cir Dig       Date:  2014 Jul-Sep

2.  Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits.

Authors:  Sergio Bárcena-Varela; Guillermo Martínez-de-Tejada; Lukas Martin; Tobias Schuerholz; Ana Gloria Gil-Royo; Satoshi Fukuoka; Torsten Goldmann; Daniel Droemann; Wilmar Correa; Thomas Gutsmann; Klaus Brandenburg; Lena Heinbockel
Journal:  Exp Mol Med       Date:  2017-06-16       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.